Home > Innovation & Research > Scientific Publications

Scientific Publications

Patients are not Schroedinger Cat's

Jordi Naval

We consider that pharma companies are obliged to understand and predict possible adverse events before entering in clinical trials with patients by using all predictive tools available

GEN Oct.15, vol.30, no.18

Mireia Coma, Jordi Naval

Systems Biology Upends Drug Reprofiling

"There are smart thieves, and there are dumb thieves. Smart ones try to swiftly fit the right keys into the right locks, knowing which doors they wish to open. Dumb thieves try desperately to fit any kind of key into any kind of lock, no matter what door, and at the end they often get caught by the police"

Innovations in Pharmaceutical Technology, 2011

Joan Bigorra, Jordi Naval

The New Science of Predictive Safety Testing

What price would a company pay to know that a compound in development had potential safety issues? New approaches to predictive safety aim to consider the whole complexity of human cellular biology by integrating all the available data, and "learning" and reproducing the real behaviour of the system - the human body - using mathematical models

NutraFoods 2010, 9: 31

Jordi Naval, Judith Farrés

Systems Biology footprint on the nutraceuticals and cosmetics arena

"Systems Biology, a new and validated integrative technology, finds many uses in the fields of cosmetics and nutraceuticals, accelerating the design of new products, and providing scientific support for health claims"

Nutr Metab, 2010, 7: 88

Judith Farrés, Albert Pujol, Mireia Coma, Jose Luis Ruiz, Jordi Naval,
José Manuel Mas, Agustí Molins, Joan Fondevila, Patrick Aloy

Revealing the molecular relationship between type 2 diabetes and the metabolic changes induced by a very-low-carbohydrate low-fat ketogenic diet

"A strong relationship between the insulin resistance pathway and the ketosis main pathway was identified, providing a possible explanation for the improvement observed in clinical trials"

Trends Pharmacol Sci. 2010 Mar;31(3):115-123

Pujol A., Mosca R., Farrés J &: Aloy P.

Unveiling the role of network and systems biology in drug discovery

"Network and systems biology offer a novel way of approaching drug discovery by developing models that consider the global physiological environment of protein targets, and the effects of modifying them, without losing the key molecular details.

Here we review some recent advances in network and systems biology applied to human health , and discuss how they can have a big impact on some of the most interesting areas of drug discovery. In particular, we claim that network biology will play a central part in the development of novel polypharmacology strategies to fight complex multifactorial diseases, where efficacious therapies will need to center on altering entire pathways rather than single proteins.

We briefly present new developments in the two areas where we believe network and system biology strategies are more likely to have an immediate contribution: predictive toxicology and drug repurposing."

FEBS Lett. 2008 Apr 9; 582(8):1259-65

Pache R.A., Zanzoni A., Naval J., Mas, J.M & Aloy P.

Towards a molecular characterisation of pathological pathways

"The dominant conceptual reductionism in drug discovery has resulted in many promising drug candidates to fail during the last clinical phases, mainly due to the lack of knowledge about the patho-physiological pathways they are acting on.

Consequently, to increase the revenues of the drug discovery process, we need to improve our understanding of the molecular mechanisms underlying complex cellular processes and consider each potential drug target in its full biological context.

Here, we review several strategies that combine computational and experimental techniques, and suggest a systems pathology approach that will ultimately lead to a better comprehension of the molecular bases of disease."

• Copyright (c) Anaxomics 2010
• Privacy policy
• Legal disclaimer